Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Preparation and Evaluation of PGE1-ethyl Ester Intraurethral Solutions for Erectile Dysfunction

PGE1-ethyl Ester함유 발기부전 치료용 요도주입 액제의 제조 및 평가

  • Published : 2006.08.21
Download PDF
⟨ Previous Next ⟩

Abstract

[ $PGE_1$ ]-ethyl ester intraurethral solutions were prepared in ethanol/propylene glycol mixture with penetration enhancer and viscosity-enhancing agent. The stability of $PGE_1$-ethyl ester in intraurethral solution was investigated at various temperature. Simultaneous determination of $PGE_1$-ethyl ester and $PGE_1$ was performed using a validated HPLC technique. In pentobarbital anesthetized cats, increase in intracavernous pressure(ICP), increase in penile length and duration of erectile response were determined after intraurethral application of $PGE_1$-ethyl ester solutions. $PGE_1$-ethyl ester solutions, when instilled into the eyes of rabbits, produces no noticeable irritation, or slight transient conjunctival irritation. From these results, ocular irritation of this solutions was judged as practically non-irritating. The stability study indicates that the therapeutically effective content in solution is well maintained for 46 weeks or longer when they are stored at $4^{\circ}C$. After intraurethral application of $PGE_1$-ethyl ester, ICP was increased and penile erection was induced. $PGE_1$-ethyl ester intraurethral solutions for erectile dysfunction could be developed and evaluated by employing feline erection model.

Keywords

References

  1. NIH concensus conference. Development panel on impotence: impotence, JAMA, 270, 83-90 (1993) https://doi.org/10.1001/jama.270.1.83
  2. R. E. Nellans, L. R. Ellis and D. Kramer-Levien, Pharma- cological erection: diagnosis and treatment applications in 69 patients, J. Urol., 138, 52-54 (1987) https://doi.org/10.1016/S0022-5347(17)42985-5
  3. P. Halter, Trends in urology, Med. Device Diagn. Industry, 12, 52-54 (1990)
  4. J. R. White and R. K. Campbell, Drug induced male sexual dysfunction. U.S. Pharmacist Diabetes Supplement. Complications, November, 44-47 (1990)
  5. H. Porst, The rationale for prostaglandin $E_1$ in erectile failure: a survey of worldwide experience, J. Urol., 155, 802-815 (1996) https://doi.org/10.1016/S0022-5347(01)66315-8
  6. O. I. Linet and F. G. Orrinc, Efficacy and safety of intraca- vernosal alprostadil in men with erectile dysfunction, N. Engl. J. Med., 334, 873-877 (1996)
  7. L. Garcia-Reboll, J. P. Mulhall and I. Goldstein, Drugs for the treatment of impotence, Drugs & Aging, 11, 140-151 (1997) https://doi.org/10.2165/00002512-199711020-00006
  8. E. D. Kim and K. T. Mcvary, Topical prostaglandin $E_1$ for the treatment of erectile dysfunction, J. Urol., 153, 1828-1830 (1995) https://doi.org/10.1016/S0022-5347(01)67323-3
  9. H. Wendel and F. J. Braun, Transdermal prostaglandin composition, US Patent 5,380,760, 1995
  10. M.-T. Sheu, L.-H. Lin, B. W. Spur, P. Y.-K. Wong and H.-S. Chiang, Investigation of the percutaneous penetration of prostaglandin $E_1$ and its ethyl ester, J. Control. Rel., 55, 153-160 (1998) https://doi.org/10.1016/S0168-3659(98)00045-5
  11. R. G. Stehle and T. O. Oesterling, Stability of prostaglandin $E_1$ and dinoprostone(prostaglandin $E_2$) under strongly acidic and basic condition, J. Pharm. Sci., 66, 1590-1595 (1977) https://doi.org/10.1002/jps.2600661123
  12. D. C. Monkhouse, L. Van Campen and A. J. Aguiar, Kinetics of dehydration and isomerization of prostaglandins $E_1$ and $E_2$, J. Pharm. Sci., 62, 576-580 (1973) https://doi.org/10.1002/jps.2600620406
  13. H. Padma-Nathan, W. J. Hellstrom, F. E. Kaiser, R. F. Labasky, T. F. Lue, W. E. Nolten, P. C. Norwood, C. A. Peterson, R. Shabsigh, P. Y. Tam, V. A. Place and A. Gesundheit, Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection(MUSE) Study Group, N. Engl. J. Med., 336, 1-7 (1997) https://doi.org/10.1056/NEJM199701023360101
  14. G. Williams, C.-C. Abbou, E. T. Amar, P. Desvaux, T. A. Flam, G. A. B. Lycklama a Nijeholt, S. F. Lynch, R. J. Morgan, S. C. Muller, H. Porst, J. P. Pryor, P. Ryan, U. K. F. Witzsch, M. M. Hall, V. A. Place, A. P. Spivack and N. Gesundheit, Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Brit. J. Urol., 81, 889-894 (1998) https://doi.org/10.1046/j.1464-410x.1998.00703.x
  15. A. Babar, H. M. Fares and F. M. Plakogiannis, In vitro release of testosterone from suppository bases and in vivo absorption studies in human males, J. Pharm. Sci., 83, 389-391 (1993)
  16. N. Aoyagi, N. Kaniwa and M. Uchiyama, Inter-laboratory reproducibility of release tests for suppositories, Drug. Develop. Ind. Pharm., 21, 176-183 (1995)
  17. W. J. G. Hellstrom, R. Wang, P. J. Kadowitz and F. R. Domer, Potassium channel agonists cause penile erection in cats, Int. J. Impot. Res., 53, 1365-1372 (1992)
  18. R. Wang, F. R. Domer, S. C. Sika, P. J. Kadowitz and W. J. Hellstrom, Nitric oxide mediates penile erection in cats, J. Urol., 151, 234-237 (1994) https://doi.org/10.1016/S0022-5347(17)34923-6
  19. H. C. Champion, R. Wang, W. J. Hellstrom and P. J. Kadowitzs, Noclceptin, a novel endogenous ligand for the ORL1 receptor, has potent erectile activity in the cat, Am. J. Physiol., 273, E214-E219 (1997) https://doi.org/10.1152/ajpcell.1997.273.1.C214
  20. H. C. Champion, R. Wang, J. A. Santiago, W. A. Murphy, D. H. Coy, P. J. Kadowitz and W. J. G. Hellstrom, Comparison of responses to adrenomedullin and calcitonin gene-related peptide in the feline erection model, J. Androl., 18, 513-521 (1997)
  21. H. C. Champion, T. J. Bivalacqua, R. Wang, P. J. Kadowitz, L. K. Keefer, J. E. Saavedra, J. A. Hrabie, P. C. Doherty and W. J. G. Hellstrom, Induction of penile erection by intracavernosal and transurethral administration of novel nitric oxide donors in the cat, J. Urol., 161, 2013-2019 (1999) https://doi.org/10.1016/S0022-5347(05)68875-1
  22. J. T. Carstensen, Drug stability, principles and practices, second edition, Marcel Dekker, Inc., New York. 35-48, 1995